Paper Details

  1. Home
  2. Paper Details

Rizatriptan versus usual care in long-term treatment of migraine.

Author: SilbersteinS D

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Rizatriptan, a 5-HT1B/1D receptor agonist, was found to be effective in the long-term treatment of migraine, providing consistent pain relief and complete pain relief over a 12-month period. Side effects were generally mild and transient.
Paper Details　
Original Abstract of the Article :
Because of the recurrent nature of migraine, a major concern with pharmacologic therapy is whether it will remain effective, safe, and tolerable over the long term. The development of sumatriptan offered an improvement in migraine therapy, although concerns remain about chest symptoms associated wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11089516

データ提供：米国国立医学図書館（NLM）

Long-Term Relief from Migraines: Rizatriptan Shows Promise

Migraines are a debilitating condition that affects millions worldwide. The quest for effective and long-lasting migraine treatments is a major challenge in neurology. This study, published in the journal [Journal Name], explores the long-term efficacy of rizatriptan, a triptan medication, in managing migraines.

The research compared the effects of rizatriptan to usual care, which involved a combination of medications used to treat acute migraine attacks. The study showed that rizatriptan consistently provided superior pain relief and complete pain relief compared to usual care, even after 12 months of treatment! While side effects were reported, they were generally mild and transient. Nausea, dizziness, and somnolence were the most common.

Hope on the Horizon for Migraine Sufferers

The findings suggest that rizatriptan could be a viable long-term solution for migraine sufferers. The sustained pain relief without significant side effects is encouraging news for those seeking enduring migraine management. It’s like finding a cool, refreshing oasis in the vast and sometimes harsh desert of migraine treatment!

Managing Migraines: A Journey for Everyone

For those living with migraines, this research provides a glimmer of hope. While rizatriptan may not be the perfect solution for everyone, it represents a significant step forward in managing this chronic condition. It's a reminder that even in the seemingly endless expanse of medical research, breakthroughs can emerge, bringing relief to those who need it most.

Dr.Camel's Conclusion

Rizatriptan emerges as a promising long-term treatment option for migraines, providing consistent pain relief and improving quality of life. This study offers hope to migraine sufferers seeking lasting relief from their condition. It's a reminder that even in the seemingly endless expanse of medical research, breakthroughs can emerge, bringing hope and healing to those who need it most.

Date :
  1. Date Completed 2000-12-07
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

11089516

DOI: Digital Object Identifier

11089516

Related Literature

Article Analysis
・Side Effects of rizatriptan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.